Evaluation of toll-like receptors as prognostic biomarkers in gastric cancer: high tissue TLR5 predicts a better outcome
Evaluation of toll-like receptors as prognostic biomarkers in gastric cancer: high tissue TLR5 predicts a better outcome
复制标题
DOI：
10.1038/s41598-019-49111-2
复制
发表时间：
2019-08-29
影响因子：
4.6
通讯作者：
Haglund, Caj
中科院分区：
文献类型：
--
作者：
Kasurinen, Aaro;Hagstrom, Jaana;Haglund, Caj
Toll样受体（TLR）是先天免疫中的关键蛋白，似乎有助于癌发生中的炎症环境。因此，我们的目的是评估TLR 1，TLR 2，TLR 4，TLR 5，TLR 7和TLR 9的组织表达作为胃癌的潜在预后生物标志物。我们应用免疫组织化学方法研究了2000年至2009年在芬兰赫尔辛基大学医院外科手术的313例胃腺癌患者的组织样本。研究的每种TLR的高表达与彼此的高表达以及与膀胱型组织学相关（所有p < 0.001）。高TLR 5患者的5年疾病特异性生存率为53.4%（95%置信区间[CI] 43.4-63.4），而低TLR 5患者的5年疾病特异性生存率为37.6%（95% CI 30.0-45.2; p = 0.014）。TLR 5高表达是预后较好的标志，尤其是在II期疾病（风险比[HR] 0.33; 0.13-0.83; p = 0.019）或卵巢癌（HR 0.58; 95%CI 0.34-0.98; p = 0.043）患者中。在这项研究中，我们首次表明，高TLR 5组织表达可以识别具有更好预后的胃癌患者，特别是那些患有II期疾病或直肠癌的患者。
Toll-like receptors (TLRs), key proteins in innate immunity, appear to contribute to the inflammatory environment in carcinogenesis. Thus, we aimed to evaluate the tissue expressions of TLR1, TLR2, TLR4, TLR5, TLR7, and TLR9 as potential prognostic biomarkers in gastric cancer. We applied immunohistochemistry to study tissue samples from 313 patients operated on for gastric adenocarcinoma between 2000 and 2009 at the Department of Surgery, Helsinki University Hospital, Finland. A high expression of each TLR studied associated with the high expression of each other and with the intestinal-type histology (p < 0.001 for all). Five-year disease-specific survival among patients with a high TLR5 was 53.4% (95% confidence interval [CI] 43.4-63.4), whereas among patients with a low TLR5 it was 37.6% (95% CI 30.0-45.2; p = 0.014). A high TLR5 expression functioned as a marker of a better prognosis, particularly among those with a stage II disease (hazard ratio [HR] 0.33; 0.13-0.83; p = 0.019) or an intestinal-type cancer (HR 0.58; 95% CI 0.34-0.98; p = 0.043). In this study we show, for the first time, that a high TLR5 tissue expression may identify gastric cancer patients with a better prognosis, particularly among those with a stage II disease or an intestinal-type cancer.